| 1.23 -0.04 (-3.15%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.59 |
1-year : | 1.78 |
| Resists | First : | 1.36 |
Second : | 1.52 |
| Pivot price | 1.29 |
|||
| Supports | First : | 1.1 |
Second : | 0.91 |
| MAs | MA(5) : | 1.34  |
MA(20) : | 1.26 |
| MA(100) : | 1.22 |
MA(250) : | 1.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 48.9 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 3.77 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed above bottom band by 30.5%. Bollinger Bands are 8.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.27 | 1.27 - 1.27 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Tue, 14 Oct 2025
Allogene Therapeutics (ALLO) Impacted by Patent Dispute Involving Cellectis - GuruFocus
Tue, 14 Oct 2025
Allogene licensor Cellectis faces patent case (ALLO:NASDAQ) - Seeking Alpha
Tue, 14 Oct 2025
Allogene Therapeutics Faces Potential Patent Infringement Issues - TradingView
Fri, 10 Oct 2025
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Fri, 10 Oct 2025
Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha
Fri, 10 Oct 2025
JP Morgan Downgrades Allogene Therapeutics (ALLO) to Underweight - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 222 (M) |
| Shares Float | 165 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 74 (%) |
| Shares Short | 19,200 (K) |
| Shares Short P.Month | 19,940 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | -55.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.82 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -173 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -1.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|